MedTrace Logo

Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa

NCT02320812 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-03-05

Study results available
· View outcomes & findings →

Summary

This study evaluates the safety and potential activity of a single dose of live human retinal progenitor cells (jCell) administered to adults with retinitis pigmentosa. Four different dose levels of cells will be assessed in each of two groups of patients.

Conditions

  • Retinitis Pigmentosa (RP)

Interventions

BIOLOGICAL

human retinal progenitor cells

single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)

Sponsors & Collaborators

  • California Institute for Regenerative Medicine (CIRM)

    collaborator OTHER

  • jCyte, Inc

    lead INDUSTRY

Principal Investigators

  • Baruch Kuppermann, MD · Gavin Herbert Eye Institute, UCI, Irvine, CA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2017-07-19
Completion
2017-07-19

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02320812 on ClinicalTrials.gov